|
|
Review of microdialysis in brain tumors, from concept to application: First
Annual Carolyn Frye-Halloran Symposium
Ramsis K. Benjamin, Fred H. Hochberg, Elizabeth Fox, Peter M. Bungay, William
F. Elmquist, Clinton F. Stewart, James M. Gallo, Jerry M. Collins, Robert P.
Pelletier, John F. de Groot, Robert C. Hickner, Idil Cavus, Stuart A. Grossman,
and O. Michael Colvin
Brain Tumor Center, Massachusetts General Hospital, Boston, MA
02114 (R.K.B., F.H.H.); National Cancer Institute, Bethesda, MD 20892 (E.F.);
National Institutes of Health, Bethesda, MD 20892 (P.M.B); Department of
Pharmaceutics, University of Minnesota, Minneapolis, MN 55455 (W.F.E.); St. Jude
Children’s Research Hospital, Memphis, TN 38105 (C.F.S.); Department of
Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111 (J.M.G.);
Laboratory of Clinical Pharmacology, Center for Drug Evaluation and Research,
Food and Drug Administration, Rockville, MD 20857 (J.M.C.); CMA Microdialysis,
North Chelmsford, MA 01863 (R.P.P); The University of Texas M.D. Anderson Cancer
Center, Houston, TX 77030 (J.F.D.); Human Performance Laboratory, East Carolina
University, Greenville, NC 27858 (R.C.H.); Psychiatry Department, Yale
University, New Haven, CT 06519 (I.C.); Department of Neuro-Oncology, Sidney
Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231
(S.A.G.); Department of Medicine, Duke University Medical Center, Durham, NC
27710 (O.M.C.); USA
In individuals with brain tumors, pharmacodynamic and pharmacokinetic studies of
therapeutic agents have historically used analyses of drug concentrations in
serum or cerebrospinal fluid, which unfortunately do not necessarily reflect
concentrations within the tumor and adjacent brain.
This review article introduces to neurological and medical oncologists, as well
as pharmacologists, the application of microdialysis in monitoring drug
metabolism and delivery within the fluid of the interstitial space of brain
tumor and its surroundings.
Microdialysis samples soluble molecules from the extracellular fluid via a
semipermeable membrane at the tip of a probe.
In the past decade, it has been used predominantly in neurointensive care in the
setting of brain trauma, vasospasm, epilepsy, and intracerebral
hemorrhage.
At the first Carolyn Frye-Halloran Symposium held at Massachusetts General
Hospital in March 2002, the concept of microdialysis was extended to
specifically address its possible use in treating brain tumor patients.
In doing so we provide a rationale for the use of this technology by a National
Cancer Institute consortium, New Approaches to Brain Tumor Therapy, to measure
levels of drugs in brain tissue as part of phase 1 trials.
©
2003 Duke University Press
Source: http://lysander.ingentaselect.com/cgi-bin/linker?ini=dup_no&reqidx=/cw/dup/15228517/v6n1/s11/p65
|
